Literature DB >> 3009317

Polymorphism of the HLA DR1 haplotype in the Israeli population investigated at the serological, cellular, and genomic levels.

N Cohen, A Friedmann, F Szafer, A Amar, D Cohen, C Brautbar.   

Abstract

In the present report, we used serological, cellular, and restriction fragment length polymorphism (RFLP) to investigate the DR1 haplotype in the Israeli population. We describe an Israeli homozygous typing cell (HTC), HLA-Dw"LVA", which defines a new lymphocyte-activating determinant associated with Bw65, DR1 and distinct from Dw1. The parents of this donor, non-Ashkenazi Algerian Jews, are first cousins and share HLA-Cw8,Bw65,BfS,DR1,DQw1,DPw4. No specificity could be assigned to HLA-Dw"LVA" using the 91 Ninth Workshop HTCs. Two families and forty unrelated DR1 individuals were studied with Dw"LVA" and a panel of DR1/Dw1 HTCs. HLA-Dw"LVA" showed segregation as a single determinant within families. This new specificity was present in 24 out of 40 (60%) unrelated DR1 individuals, indicating that in the Israeli population Dw"LVA" is the main lymphocyte-defined determinant associated with the serologically defined DR1 specificity, in contrast to non-Jewish Caucasoids where DR1 is significantly associated with Dw1. The vast majority of Dw"LVA"-positive carriers were also Bw65 carriers, indicating that Bw65,DR1, Dw"LVA" may represent a typical allele combination in the Israeli population. The RFLP analysis established the correlation of certain RFLPs with Dw1 and Dw"LVA". In addition, we describe a cluster of FRLPs that may correspond to a new Dw subtype associated with DR1, for which no serological and cellular reagents have been described so far.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009317     DOI: 10.1007/bf00373020

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  23 in total

Review 1.  DNA polymorphism of HLA class I and class II regions.

Authors:  D Cohen; P Paul; I Le Gall; A Marcadet; M P Font; O Cohen-Haguenauer; B Sayagh; H Cann; J M Lalouel; J Dausset
Journal:  Immunol Rev       Date:  1985-07       Impact factor: 12.988

2.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

3.  Immunofixation electrophoresis: a technique for the study of protein polymorphism.

Authors:  C A Alper; A M Johnson
Journal:  Vox Sang       Date:  1969-11       Impact factor: 2.144

4.  Five HLA-D clusters associated with HLA-DR4.

Authors:  N L Reinsmoen; F H Bach
Journal:  Hum Immunol       Date:  1982-06       Impact factor: 2.850

5.  Polymorphic restriction endonuclease fragment segregates and correlates with the gene for HLA-B8.

Authors:  H M Cann; L Ascanio; P Paul; A Marcadet; J Dausset; D Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

6.  HLA-D clusters associated with DR4 in the Japanese population.

Authors:  Y Nose; K Sato; M Nakagawa; K Kondoh; H Inouye; K Tsuji
Journal:  Hum Immunol       Date:  1982-11       Impact factor: 2.850

7.  HLA polymorphism in Israel. 9. An overall comparative analysis.

Authors:  B Bonné-Tamir; J G Bodmer; W F Bodmer; P Pickbourne; C Brautbar; E Gazit; S Nevo; R Zamir
Journal:  Tissue Antigens       Date:  1978-03

8.  Definition of a new DR2 short associated HLA-D specificity with the Ninth Histocompatibility Workshop reagents.

Authors:  N Cohen; A Amar; C Brautbar
Journal:  Tissue Antigens       Date:  1984-09

9.  New HLA-D alleles associated with DR1 and DR2.

Authors:  N Suciu-Foca; M Godfrey; G Khan; K Woodward; C Rohowsky; E Reed; M Hardy; K Reemtsma
Journal:  Tissue Antigens       Date:  1981-03

10.  Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogenic proliferative and cytotoxic responses.

Authors:  S Shaw; A H Johnson; G M Shearer
Journal:  J Exp Med       Date:  1980-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.